Targeting the Peripheral Immune System as a Novel Therapeutic Approach in Alzheimer’s Disease

Time: 11:30 am
day: Day Two


  • Targeting the PD-1/PD-L1 immune checkpoint pathway in Alzheimer’s disease, to portray a unique therapeutic approach, not limited to any specific pathologyassociated factor (e.g. amyloid or tau)
  • Utilizing studies in amyloidosis and tauopathy mouse models to highlight that our therapeutic approach activates a common mechanism of action that starts with evoking a transient immune response in the periphery, and culminates with central effects on brain pathology, local tissue inflammation, and function
  • Presenting translational pharmacology showing that IBC-Ab002 is a novel fully human anti-PD-L1 antibody, engineered with differentiating characteristics tailored to treat Alzheimer’s disease